Carter Gould
Stock Analyst at Cantor Fitzgerald
(4.22)
# 1,489
Out of 5,043 analysts
638
Total ratings
53.2%
Success rate
6.4%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Rated: Buy | $285 → $290 | $276.47 | +4.89% | 51 | Oct 8, 2026 | |
| AMGN Amgen | Rated: Hold | $400 → $440 | $414.87 | +6.06% | 52 | Oct 8, 2026 | |
| BMY Bristol-Myers Squibb Company | Rated: Hold | $59 → $53 | $59.12 | -10.35% | 37 | Oct 8, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,410 → $1,440 | $1,179.27 | +22.11% | 102 | Oct 8, 2026 | |
| MRK Merck & Co. | Rated: Hold | $120 → $145 | $145.60 | -0.41% | 45 | Oct 8, 2026 | |
| PFE Pfizer | Rated: Hold | $27 → $28 | $28.28 | -0.99% | 62 | Oct 8, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $155 | $151.17 | +2.53% | 50 | Aug 4, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $590 → $595 | $510.08 | +16.65% | 11 | Aug 4, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $750 → $795 | $746.54 | +6.49% | 53 | Jul 30, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | n/a | $62.91 | - | 18 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $71.38 | n/a | 2 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $225.71 | n/a | 45 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.31 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $52.13 | n/a | 24 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $19.90 | n/a | 14 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $1.23 | n/a | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.08 | n/a | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $142.44 | n/a | 29 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $160 | $190.37 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $100.60 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €82.75 | €137.85 | n/a | 1 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $82 → $86 | $112.79 | n/a | 4 | Jul 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $94 | $549.16 | n/a | 1 | May 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $4 | $2.50 | n/a | 2 | Feb 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $2.8 | $7.06 | n/a | 2 | Jan 11, 2019 |
AbbVie
Oct 8, 2026
Rated: Buy
Price Target: $285 → $290
Current: $276.47
Upside: +4.89%
Amgen
Oct 8, 2026
Rated: Hold
Price Target: $400 → $440
Current: $414.87
Upside: +6.06%
Bristol-Myers Squibb Company
Oct 8, 2026
Rated: Hold
Price Target: $59 → $53
Current: $59.12
Upside: -10.35%
Eli Lilly and Company
Oct 8, 2026
Rated: Buy
Price Target: $1,410 → $1,440
Current: $1,179.27
Upside: +22.11%
Merck & Co.
Oct 8, 2026
Rated: Hold
Price Target: $120 → $145
Current: $145.60
Upside: -0.41%
Pfizer
Oct 8, 2026
Rated: Hold
Price Target: $27 → $28
Current: $28.28
Upside: -0.99%
Gilead Sciences
Aug 4, 2026
Reiterated: Buy
Price Target: $155
Current: $151.17
Upside: +2.53%
Vertex Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $590 → $595
Current: $510.08
Upside: +16.65%
Regeneron Pharmaceuticals
Jul 30, 2026
Reiterated: Buy
Price Target: $750 → $795
Current: $746.54
Upside: +6.49%
Cytokinetics
Feb 25, 2026
Reiterated: Buy
Price Target: n/a
Current: $62.91
Upside: -
Jun 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $71.38
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $225.71
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $9.31
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $52.13
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $19.90
Upside: n/a
Nov 8, 2024
Rated: Buy
Price Target: $9
Current: $1.23
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $12
Current: $2.08
Upside: n/a
Oct 31, 2024
Reiterated: Buy
Price Target: $160
Current: $142.44
Upside: n/a
Jan 11, 2023
Rated: Hold
Price Target: $160
Current: $190.37
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $100.60
Upside: n/a
Feb 27, 2020
Initiated Coverage: Buy
Price Target: €82.75
Current: €137.85
Upside: n/a
Jul 31, 2019
Reiterated: Hold
Price Target: $82 → $86
Current: $112.79
Upside: n/a
May 17, 2019
Upgraded: Hold
Price Target: $94
Current: $549.16
Upside: n/a
Feb 1, 2019
Downgraded: Hold
Price Target: $16 → $4
Current: $2.50
Upside: n/a
Jan 11, 2019
Reiterated: Hold
Price Target: $6 → $2.8
Current: $7.06
Upside: n/a